Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Debt (2016 - 2025)

Altimmune (ALT) has disclosed Total Debt for 13 consecutive years, with $14.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt changed N/A to $14.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.4 million, a N/A change, with the full-year FY2022 number at $4.6 million, down 39.28% from a year prior.
  • Total Debt was $14.4 million for Q3 2025 at Altimmune, up from $14.3 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $14.4 million in Q3 2025 to a low of $1.5 million in Q2 2022.
  • A 4-year average of $5.4 million and a median of $4.4 million in 2023 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: skyrocketed 312.59% in 2021, then plummeted 39.28% in 2022.
  • Altimmune's Total Debt stood at $7.5 million in 2021, then tumbled by 39.28% to $4.6 million in 2022, then decreased by 6.02% to $4.3 million in 2023, then skyrocketed by 235.54% to $14.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Total Debt are $14.4 million (Q3 2025), $14.3 million (Q2 2025), and $4.3 million (Q3 2023).